Mutual of America Capital Management LLC Purchases Shares of 12,629 Ralliant Corporation $RAL

Mutual of America Capital Management LLC acquired a new position in shares of Ralliant Corporation (NYSE:RAL) during the third quarter, HoldingsChannel reports. The firm acquired 12,629 shares of the company’s stock, valued at approximately $552,000.

Several other large investors also recently made changes to their positions in the stock. Truist Financial Corp acquired a new position in Ralliant during the second quarter worth $1,409,000. Robeco Institutional Asset Management B.V. bought a new position in shares of Ralliant in the 2nd quarter valued at about $4,802,000. QRG Capital Management Inc. bought a new position in shares of Ralliant in the 2nd quarter valued at about $230,000. 111 Capital acquired a new position in shares of Ralliant during the 2nd quarter worth about $351,000. Finally, Drake & Associates LLC bought a new stake in shares of Ralliant in the 2nd quarter valued at about $413,000.

Ralliant Trading Up 2.1%

Shares of Ralliant stock opened at $54.62 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.03 and a current ratio of 1.49. The firm has a 50-day moving average of $51.78 and a 200-day moving average of $46.76. Ralliant Corporation has a 52-week low of $40.70 and a 52-week high of $55.25. The stock has a market cap of $6.16 billion and a PE ratio of 43.01.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.02. The business had revenue of $529.10 million during the quarter, compared to analyst estimates of $519.14 million.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Ralliant’s dividend payout ratio is currently 15.75%.

Analyst Ratings Changes

RAL has been the subject of several research analyst reports. Oppenheimer lifted their target price on Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $53.00 to $61.00 in a research report on Monday, December 8th. Truist Financial initiated coverage on shares of Ralliant in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective on the stock. Barclays raised their target price on shares of Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Finally, Royal Bank Of Canada lifted their target price on shares of Ralliant from $45.00 to $52.00 and gave the stock a “sector perform” rating in a report on Friday, November 7th. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Ralliant currently has a consensus rating of “Moderate Buy” and an average target price of $58.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.